Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/karger/observational-monitoring-of-patients-with-aplastic-anemia-and-low-CnF3w3wszf
References (32)
-
R. Guariglia, M. Martorelli, O. Villani, G. Pietrantuono, G. Mansueto, Fiorella D’Auria, Vitina Grieco, G. Bianchino, R. Lerose, G. Bochicchio, P. Musto (2011)
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.Leukemia research, 35 5
-
L. Anderson, S. Holden, B. Davis, E. Prescott, C. Charrier, N. Bunce, D. Firmin, B. Wonke, J. Porter, J. Walker, D. Pennell (2001)
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.European heart journal, 22 23
-
N. Shenoy, N. Vallumsetla, E. Rachmilewitz, A. Verma, Y. Ginzburg (2014)
Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.Blood, 124 6
-
A. List, M. Baer, D. Steensma, A. Raza, Jason Esposito, Noelia Martinez-Lopez, C. Paley, J. Feigert, E. Besa (2012)
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 17
-
E. Messa, D. Cilloni, F. Messa, F. Arruga, Antonella Roetto, G. Saglio (2008)
Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary MyelofibrosisActa Haematologica, 120
-
Qian Zhang, B. Hou, Lu Wang, Xiao-Ying Wang, F. Feng, Bin Jiang, Hong-xia Shi, Yining Ma, Hui Liu, B. Han, Yong-qiang Zhao (2013)
[Significance of magnetic resonance imaging in the detection of iron overload].Zhonghua yi xue za zhi, 93 44
-
S. Pasricha, D. Frazer, D. Bowden, G. Anderson (2013)
Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.Blood, 122 1
-
N. Gattermann, C. Finelli, M. Porta, P. Fenaux, M. Stadler, A. Guerci-Bresler, M. Schmid, K. Taylor, D. Vassilieff, D. Habr, A. Marcellari, B. Roubert, C. Rose (2012)
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromesHaematologica, 97
-
M. Cappellini, M. Bejaoui, L. Ağaoğlu, D. Canatan, M. Capra, A. Cohen, G. Drelichman, M. Economou, S. Fattoum, A. Kattamis, Y. Kilinç, S. Perrotta, A. Piga, John Porter, L. Griffel, V. Dong, Joan Clark, Y. Aydinok (2011)
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.Blood, 118 4
-
S. Zwart, Jennifer Morgan, Scott Smith (2013)
Iron status and its relations with oxidative damage and bone loss during long-duration space flight on the International Space Station.The American journal of clinical nutrition, 98 1
-
M. Takatoku, T. Uchiyama, S. Okamoto, Y. Kanakura, K. Sawada, M. Tomonaga, S. Nakao, T. Nakahata, M. Harada, T. Murate, K. Ozawa (2007)
Retrospective nationwide survey of Japanese patients with transfusion‐dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortalityEuropean Journal of Haematology, 78
-
A. Mainous, R. Tanner, M. Hulihan, Mirna Amaya, T. Coates (2014)
The impact of chelation therapy on survival in transfusional iron overload: a meta‐analysis of myelodysplastic syndromeBritish Journal of Haematology, 167
-
J. Carpenter, T. He, P. Kirk, Michael Roughton, Lisa Anderson, S. Noronha, M. Sheppard, J. Porter, J. Walker, J. Wood, Renzo Galanello, G. Forni, Gualtiero Catani, Gildo Matta, Suthat Fucharoen, Adam Fleming, Michael House, G. Black, D. Firmin, T. Pierre, D. Pennell (2011)
On T2* Magnetic Resonance and Cardiac IronCirculation, 123
-
S. Nakao (2016)
Diagnostic problems in acquired bone marrow failure syndromesInternational Journal of Hematology, 104
-
Rui Jiang, J. Manson, J. Meigs, Jing Ma, N. Rifai, F. Hu (2004)
Body iron stores in relation to risk of type 2 diabetes in apparently healthy women.JAMA, 291 6
-
J. Lee, S. Yoon, Zhi-xiang Shen, A. Ganser, H. Hsu, D. Habr, G. Domokos, B. Roubert, J. Porter (2010)
Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.Blood, 116 14
-
J. Neukirchen, F. Fox, A. Kündgen, K. Nachtkamp, C. Strupp, R. Haas, U. Germing, N. Gattermann (2012)
Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.Leukemia research, 36 8
-
J Virtanen, T Pudas, J Ratilainen, J Saunavaara, M Komu, R Parkkola (2012)
Iron overload: accuracy of in-phase and out-of-phase MRI as a quick method to evaluate liver iron load in haematological malignancies and chronic liver disease.The British journal of radiology, 85 1014
-
Donald Johnston, Lawrence Rice, G. Vick, Thomas Hedrick, Roxann Rokey (1989)
Assessment of tissue iron overload by nuclear magnetic resonance imaging.The American journal of medicine, 87 1
-
D. Pennell, J. Porter, A. Piga, Y. Lai, A. El‐Beshlawy, K. Belhoul, M. Elalfy, A. Yeşilipek, Y. Kilinç, T. Lawniczek, D. Habr, M. Weisskopf, Yiyun Zhang, Y. Aydinok (2014)
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).Blood, 123 10
-
Xuan Zheng, Tao Jiang, Hong Wu, Dezeng Zhu, Ling Wang, Ruirui Qi, Min Li, C. Ling (2011)
Hepatic iron stores are increased as assessed by magnetic resonance imaging in a Chinese population with altered glucose homeostasis.The American journal of clinical nutrition, 94 4
-
G. Chouliaras, A. Kattamis, V. Berdoukas, E. Gotsis, S. Mavrogeni, V. Ladis (2010)
Cardiac magnetic resonance in transfusion dependent thalassaemia: assessment of iron load and relationship to left ventricular ejection fractionBritish Journal of Haematology, 151
-
Y. Aydinok, A. Kattamis, M. Cappellini, A. El‐Beshlawy, R. Origa, Mohsen Elalfy, Y. Kilinç, S. Perrotta, Z. Karakaş, V. Viprakasit, D. Habr, N. Constantinovici, Junwu Shen, J. Porter (2015)
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.Blood, 125 25
-
D. Steensma, N. Gattermann (2013)
When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?Best practice & research. Clinical haematology, 26 4
-
N. Gattermann, C. Finelli, M. Porta, P. Fenaux, A. Ganser, A. Guerci-Bresler, M. Schmid, K. Taylor, D. Vassilieff, D. Habr, G. Domokos, B. Roubert, C. Rose (2010)
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.Leukemia research, 34 9
-
A. Waszczuk-Gajda, K. Mądry, Rafal Machowicz, J. Drozd-Sokołowska, B. Stella‐Hołowiecka, A. Mital, A. Obara, A. Szmigielska-Kaplon, A. Sikorska, E. Subocz, W. Jędrzejczak, J. Dwilewicz-Trojaczek (2016)
Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 25 4
-
Marianna Koperdanova, J. Cullis (2015)
Interpreting raised serum ferritin levelsBMJ : British Medical Journal, 351
-
P. Kirk, M. Roughton, J. Porter, J. Walker, M. Tanner, Junaid Patel, D. Wu, Jane Taylor, M. Westwood, L. Anderson, D. Pennel (2009)
Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia majorJournal of Cardiovascular Magnetic Resonance, 11
-
J. Porter, R. Galanello, G. Saglio, E. Neufeld, E. Vichinsky, M. Cappellini, N. Olivieri, A. Piga, Melody Cunningham, D. Soulières, N. Gattermann, G. Tchernia, J. Maertens, P. Giardina, J. Kwiatkowski, G. Quarta, M. Jeng, G. Forni, M. Stadler, H. Cario, L. Debusscher, M. Porta, M. Cazzola, P. Greenberg, G. Alimena, B. Rabault, I. Gathmann, J. Ford, D. Alberti, C. Rose (2007)
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective studyEuropean Journal of Haematology, 80
-
J. Carpenter, M. Roughton, D. Pennell (2013)
International survey of T2* cardiovascular magnetic resonance in β-thalassemia majorHaematologica, 98
-
L. Anderson, M. Westwood, S. Holden, B. Davis, E. Prescott, B. Wonke, J. Porter, J. Walker, D. Pennell (2004)
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonanceBritish Journal of Haematology, 127
-
E. Fung, P. Harmatz, M. Milet, S. Ballas, L. Castro, Ward Hagar, William Owen, N. Olivieri, K. Smith-Whitley, D. Darbari, Winfred Wang, E. Vichinsky (2007)
Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi‐center study of iron overloadAmerican Journal of Hematology, 82
- Publisher
- Karger
- Copyright
- © 2017 S. Karger AG, Basel
- ISSN
- 0001-5792
- eISSN
- 1421-9662
- DOI
- 10.1159/000479422
- Publisher site
- See Article on Publisher Site
Abstract
Background: This study focuses on the iron overload (IOL) of patients with transfused aplastic anemia (AA) or a low/intermediate-1 risk of myelodysplastic syndrome (MDS). Methods: Ninety-two AA or MDS patients with IOL were prospectively recruited. Clinical data were collected every 6 months, and organ magnetic resonance imaging T2* values were collected annually. Patients with IOL were chelated. Results: Serum ferritin was correlated with liver T2* and pancreatic T2* in the AA and MDS groups. Transfusion amounts were correlated with serum ferritin values, liver T2*, and pancreatic T2* in the AA group. At the 6-month and 1-year evaluations, patients with sufficient chelation experienced significant decreases in serum ferritin, and those with decreased serum ferritin experienced an obvious increase in hemoglobin. At their 1-year-follow-up, patients with adequate chelation showed significant increases in hepatic T2*, cardiac T2*, and left ventricular ejection fraction (LVEF). Patients with decreased serum ferritin (including those without chelation) experienced an increase in hemoglobin, hepatic T2*, cardiac T2*, and LVEF. Conclusion: The transfusion amount was more reliable at predicting IOL in patients with AA than in those with MDS. Adequate iron chelation can decrease serum ferritin levels and may improve hepatic T2*, cardiac T2*, and LVEF levels. A decrease in serum ferritin, even in the absence of chelation, may also benefit patients.
Journal
Acta Haematologica – Karger
Published: Jan 1, 2017
Keywords: Aplastic anemia; Myelodysplastic syndrome; Iron overload; Magnetic resonance imaging T2*; Monitoring